FDA label 687cc397-4d4c-4188-9ad3-e164db291952

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
bec39fa0-1524-4e6b-897f-db0ef093085e
SPL ID
687cc397-4d4c-4188-9ad3-e164db291952
Version
9
Effective date
2020-08-04
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:17

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, immediately discontinue ELOCTATE and initiate appropriate treatment. ( 5.1 ) Development of Factor VIII neutralizing antibodies (inhibitors) may occur. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. ( 5.2 , 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, are possible with ELOCTATE. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ELOCTATE, including in previously untreated patients. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected or if bleeding is not controlled after ELOCTATE administration, suspect the presence of an inhibitor (neutralizing antibody). [ see Warnings and Precautions ( 5.3 )] 5.3 Monitoring Laboratory Tests Monitor plasma Factor VIII activity by performing a validated test (e.g., one stage clotting assay), to confirm that adequate Factor VIII levels have been achieved and maintained. [ see Dosage and Administration ( 2 )] Monitor for the development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected Factor VIII plasma levels are not attained, or if bleeding is not controlled with the expected dose of ELOCTATE. Use Bethesda Units (BU) to report inhibitor levels.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most frequently occurring adverse reactions (incidence >0.5% of subjects) reported in clinical trials were arthralgia, malaise, myalgia, headache, and rash. The most frequently occurring adverse reactions (>0.5% of subjects) in clinical trials were arthralgia, malaise, myalgia, headache, and rash. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact BIOGEN at 1-855-693-5628 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. ELOCTATE has been evaluated in 233 subjects in two completed studies and one ongoing extension study in previously treated patients (PTPs) with severe Hemophilia A (<1% endogenous FVIII activity or a genetic mutation consistent with severe Hemophilia A) who received at least one dose of ELOCTATE as part of either routine prophylaxis, on-demand treatment of bleeding episodes or perioperative management. Sixty-nine (29.6%) were pediatric subjects <12 years of age, 13 (5.6%) were adolescents (12 to <18 years of age), and 151 (64.8%) were adults (18 years of age and older). There were 136 subjects treated for at least 104 weeks. The total number of exposure days (EDs) was 34,746 with a median of 129 (range 1-326) exposure days per subject. The subjects received a total of 35,248 injections with a median of 136 injections of ELOCTATE (range 1-328) per subject. Adverse reactions (ARs) were reported for 11 of 233 (4.7 %) subjects treated with routine prophylaxis or episodic (on-demand) therapy. No age-specific differences in ARs were observed between pediatric and adult subjects. Table 3 summarizes the most frequently occurring adverse reactions. Additional adverse reactions, each occurring in a single subject (incidence 0.4%), include dizziness, dysgeusia, bradycardia, hypertension, hot flush, angiopathy (investigator term: vascular pain after injection of study drug), cough, lower abdominal pain, back pain, joint swelling, chest pain, feeling cold, feeling hot, and procedural hypotension. Two subjects were withdrawn from study due to adverse reactions of rash and arthralgia. In the studies, no inhibitors were detected and no events of anaphylaxis were reported. Table 3: Adverse Reactions Reported for ELOCTATE (N=233) MedDRA * System Organ Class MedDRA Preferred Term Number of Subjects n (%) * MedDRA version 15.0 Nervous system disorders Headache 2 (0.9) Skin and subcutaneous tissue disorders Rash 2 (0.9) Musculoskeletal and connective tissue disorders Arthralgia Myalgia 2 (0.9) 2 (0.9) General disorders and administration site conditions Malaise 2 (0.9) Immunogenicity Clinical trial subjects were monitored for neutralizing antibodies to Factor VIII. No subjects developed confirmed neutralizing antibodies to Factor VIII. One 25 year old subject had a transient, positive, neutralizing antibody of 0.73 BU at week 14, which was not confirmed upon repeat testing 18 days later and thereafter. The detection of antibodies that are reactive to Factor VIII is highly dependent on many factors, including the sensitivity and specificity of the assay, sample handling, timing of sample collection, concomitant medications and underlying disease. Therefore, it may be misleading to compare of the incidence of antibodies to ELOCTATE with the incidence of antibodies to other products. 6.2 Postmarketing Experience The following adverse reaction has been identified during the post-approval use of ELOCTATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Factor VIII inhibitor development

adverse reactions table

<table ID="t3" width="100%"><caption>Table 3: Adverse Reactions Reported for ELOCTATE (N=233) </caption><col width="35.900%" align="left"/><col width="41.067%" align="left"/><col width="23.033%" align="left"/><thead><tr><th align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">MedDRA</content><content styleCode="bold"><sup>* </sup></content><content styleCode="bold">System Organ Class</content></th><th align="center" valign="top" styleCode="Toprule Botrule Rrule"><content styleCode="bold">MedDRA Preferred Term</content></th><th align="center" valign="top" styleCode="Toprule Botrule Rrule"><content styleCode="bold">Number of Subjects</content> <content styleCode="bold">n (%)</content></th></tr></thead><tfoot><tr><td colspan="3" align="left" valign="top"><paragraph styleCode="footnote"><sup>*</sup>MedDRA version 15.0 </paragraph></td></tr></tfoot><tbody><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Nervous system disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Headache </td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.9) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Skin and subcutaneous tissue disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Rash </td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.9) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Musculoskeletal and connective tissue disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Arthralgia Myalgia </td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.9) 2 (0.9) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">General disorders and administration site conditions</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Malaise </td><td align="center" valign="top" styleCode="Botrule Rrule">2 (0.9) </td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.